The Analgesic Effects of Pioglitazone in the Bone Cancer Pain Rats Via Regulating the PPARγ/PTEN/mTOR Signaling Pathway in the Spinal Dorsal Horn.

Wei Gu,Yu'e Sun,Wanjie Gu,Yulin Huang,Jinhua Bo,Luyang Zhou,Zhengliang Ma,Xiaoping Gu,Wei Zhang

DOI: https://doi.org/10.1016/j.biopha.2020.110692

IF: 7.419

2020-01-01

Biomedicine & Pharmacotherapy

Abstract:Background and Objectives: Bone cancer pain (BCP) remains a difficult clinical problem. This study examined whether pioglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist, is effective for attenuating BCP, and investigated the interaction between activation of PPAR gamma and phosphatase and tensin homolog deleted from chromosome 10 (PTEN)/mammalian target of rapamycin (mTOR) signal in the spinal dorsal horn (SDH) of BCP rats. Methods: We tested the effects of intrathecal (i.t.) injection of adenovirus-mediated PTEN (Ad-PTEN), PTEN antisense oligonucleotide (Ad-antisense PTEN), mTOR inhibitor rapamycin, pioglitazone and PPAR gamma antagonist GW9662 on bone cancer-induced mechanical allodynia by measuring the paw withdrawal threshold (PWT). Western blot or immunofluorescence examined the expression of spinal PPAR gamma, PTEN, mTOR, p-mTOR and p-S6K1. Results: Bone cancer did not alter total mTOR expression but caused significant downregulation of PTEN and upregulation of p-mTOR and p-S6K1 in spinal neurons. Rapamycin markedly reduced BCP. Upregulation of spinal PTEN by i.t. Ad-PTEN significantly relieved BCP and downregulated p-mTOR and p-S6K1; while i.t. Adantisense PTEN led to the opposite effects of Ad-PTEN. Spinal PPAR gamma expression increased in BCP rats, colocalizing mainly with neurons and a few astrocytes, but not in microglia. Pioglitazone (500 mu g/day i.t. for one week, from 7 days after surgery) attenuated BCP, further increased expression of PPAR gamma, and inhibited downregulation of PTEN and upregulation of p-mTOR and p-56K1 in the SDH. Pioglitazone's analgesic effect was enhanced by Ad-PTEN and attenuated by Ad-antisense PTEN. Blockade of PPAR gamma with GW9662 (300 mu g i.t. 15 min prior to pioglitazone) reversed the effects of pioglitazone on BCP and regulations of PPAR gamma/PTEN/mTOR signal. Conclusions: Intrathecal pioglitazone administration alleviates BCP by regulating the PPAR gamma/PTEN/mTOR signal in the SDH. Our data provided new insight in the therapeutic strategy in BCP management.